Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

被引：0
|
作者：
E. Claire Dees
Jeffrey R. Infante
Roger B. Cohen
Bert H. O’Neil
Suzanne Jones
Margaret von Mehren
Hadi Danaee
Yih Lee
Jeffrey Ecsedy
Mark Manfredi
Katherine Galvin
Bradley Stringer
Hua Liu
Omar Eton
Howard Fingert
Howard Burris
机构：
[1] University of North Carolina,UNC Lineberger Comprehensive Cancer Center
[2] Sarah Cannon Research Institute,undefined
[3] Fox Chase Cancer Center,undefined
[4] Millennium Pharmaceuticals,undefined
[5] Inc.,undefined
[6] Forest Research Institute,undefined
[7] Inc.,undefined
[8] Boston University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
MLN8054; Aurora A kinase; Dose-limiting toxicity; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 954
页数：9
相关论文
共 50 条
  • [21] Effect of aurora A inhibition in cultured human tumor cells using the selective small molecule inhibitor MLN8054
    Ecsedy, Jeffrey A.
    Hoar, Kara
    Wysong, Deborah R.
    Rabino, Claudia
    Bowman, Douglas S.
    Chakravarty, Arijit
    Roy, Natalie
    CANCER RESEARCH, 2006, 66 (08)
  • [22] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [23] Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
    Chakravarty, Arijit
    Shinde, Vaishali
    Tabernero, Josep
    Cervantes, Andres
    Cohen, Roger B.
    Dees, E. Claire
    Burris, Howard
    Infante, Jeffrey R.
    Macarulla, Teresa
    Elez, Elena
    Andreu, Jordi
    Rodriguez-Braun, Edith
    Rosello, Susana
    von Mehren, Margaret
    Meropol, Neal J.
    Langer, Corey J.
    ONeil, Bert
    Bowman, Douglas
    Zhang, Mengkun
    Danaee, Hadi
    Faron-Yowe, Laura
    Gray, Gary
    Liu, Hua
    Pappas, Jodi
    Silverman, Lee
    Simpson, Chris
    Stringer, Bradley
    Tirrell, Stephen
    Veiby, Ole Petter
    Venkatakrishnan, Karthik
    Galvin, Katherine
    Manfredi, Mark
    Ecsedy, Jeffrey A.
    CANCER RESEARCH, 2011, 71 (03) : 675 - 685
  • [24] MLN8054, an orally active small molecule inhibitor, mediates tumor growth inhibition in vivo through Aurora A kinase.
    Burenkova, O
    Bond, S
    Connolly, K
    Galvin, K
    Huck, J
    Manfredi, M
    Stringer, B
    Zhang, MK
    Meetze, K
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9082S
  • [25] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Zhou, X.
    Rosen, L. S.
    Venkatakrishnan, K.
    Kurzrock, R.
    Mahalingam, D.
    Goldman, J.
    Jung, J.
    Milch, C.
    Sarantopoulos, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 168 - 168
  • [27] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Schwartz, Gary K.
    Carvajal, Richard D.
    Midgley, Rachel
    Rodig, Scott J.
    Stockman, Paul K.
    Ataman, Ozlem
    Wilson, David
    Das, Shampa
    Shapiro, Geoffrey I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
  • [28] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Gary K. Schwartz
    Richard D. Carvajal
    Rachel Midgley
    Scott J. Rodig
    Paul K. Stockman
    Ozlem Ataman
    David Wilson
    Shampa Das
    Geoffrey I. Shapiro
    Investigational New Drugs, 2013, 31 : 370 - 380
  • [29] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Heike Richly
    Annette Frost
    Dirk Scharr
    Bahar Nokay
    Ralph Graeser
    Chooi Lee
    James Hilbert
    Rainer-George Goeldner
    Oliver Fietz
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417
  • [30] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345